Grace Therapeutics Q2 2027 net loss more than doubles to $2.1 million
GRCE•GRCE•GRCE•GRCE•Grace Therapeutics’ net loss more than doubled to $2.1 million for the three months ended September 30, 2026. It reported $21.3 million in cash, planned operations funded through the end of 2028, and said the FDA requested no additional clinical data in its GTx-104 response letter.
Grace Therapeutics’ net loss more than doubled to $2.1 million in the three months ended September 30, 2026. Research and development expenses rose 50% to $900,000, while general and administrative expenses fell 30% to $1.4 million from a year earlier.
The company had $21.3 million in cash and cash equivalents at September 30, 2026, and said planned operations were funded through the end of calendar 2028. The FDA identified no clinical safety or efficacy deficiencies in its complete response letter for GTx-104 and requested no additional clinical data. A dual-source manufacturing strategy is progressing, and resubmission timing depends on which manufacturing site reaches readiness first.
